A r t i c l e s
Chromatin dynamics regulate key cellular functions that influence survival, growth and proliferation, and disruption of chromatin homeo stasis has been linked to diverse pathologic processes 1 . Methylation of lysine residues of histone, which is catalyzed by protein lysine methyl transferases (PKMTs), is a principal chromatinregulatory mecha nism involved in directing fundamental DNAtemplated processes such as transcription and DNA repair 1 . Histone methylation plays a central part in orchestrating proper programming of the genome in response to various stimuli, and aberrant signaling via lysine methyl ation has been linked to the initiation and progression of many human diseases 2 . Many nonhistone proteins are also regulated by lysine methylation, which indicates that this modification is probably a common mechanism for the modulation of proteinprotein inter actions and signaling pathways 3 .
NFκB is a transcription factor and key inducer of inflammatory responses 4, 5 . One of the principal subunits of NFκB is RelA (p65 (A001645)), which forms either a homodimer or a heterodimer with the structurally related p50 protein (A002937). Under basal conditions, most RelA is sequestered in the cytoplasm because of its association with members of the inhibitor of NFκB family of proteins 4, 5 . Stimulation of cells with NFκBactivating ligands such as the cytokine tumor necrosis factor (TNF) results in degradation of these inhibitors of NFκB and translocation of the released NFκB to the nucleus, where it directs various transcriptional programs 5, 6 . In addition to that canonical pathway, there are several additional mechanisms that regulate and finetune NFκB signaling and activa tion of target genes 7 . For example, various posttranslational modifi cations of RelA influence the specificity, transcriptional activity and activation kinetics of RelA target genes. Furthermore, even in resting conditions, a population of RelA is present in the nucleus, bound at chromatin; however, the functional relevance of this constitutively nuclear population is not known.
Deregulation of NFκB signaling is linked to many human diseases, including cancer and autoimmune disorders 8 . Thus, understanding the full range of molecular mechanisms that modulate this factor in response to diverse conditions has important biological and clinical implications. Here we screened over 40 known and candidate human PKMTs for methylation of RelA in vitro. We identify SETD6 (SET domain-containing protein 6) as a PKMT that monomethylated RelA at Lys310 (RelAK310me1). The ankryin repeat of the PKMT A r t i c l e s GLP (G9Alike protein) functioned as a recognition module for RelAK310me1, which links this mark to localized methylation of histone H3 Lys9 (H3K9) and repressed chromatin at RelAK310me1 occupied genes 9, 10 . The SETD6initiated lysinemethylation signaling cascade acted to restrain activation of NFκBmediated inflammatory responses in diverse cell types. This repressive pathway was terminated by phosphorylation of RelA at Ser311 by the atypical protein kinase PKCζ (A001934) 11 , which blocked recognition of RelAK310me1 by GLP to promote the expression of target genes of RelA. Together our findings identify SETD6 as a previously uncharacterized regulator of the NFκB network, identify the ankryinrepeat domain of GLP as an effector of methylated RelA, describe a metazoan example of a methylationphosphorylation switch on a nonhistone proteins, and demonstrate a new paradigm for how integrated crosstalk between modifications on transcription factors and histones modulates key physiological and pathological programs.
RESULTS

Monomethylation of RelA at Lys310 by SETD6
To identify additional activities for predicted PKMT enzymes and lysinemethylation events, we screened most of the SET domaincontaining proteins present in the human proteome for in vitro catalytic activity on various histone and nonhistone candidate substrates (Supplementary Table 1 and data not shown). SETD6, a previously uncharacterized PKMT, methylated an Nterminal RelA polypeptide encompassing amino acids 1431 (RelA(1-431)) but not a Cterminal polypeptide (residues 430-531; Fig. 1a and Supplementary Fig. 1a,b) . Substitution of individual lysine residues with arginine in RelA(1-431) identified Lys310 as the target site of SETD6 (Fig. 1b) . In contrast, SET7SET9, which methylates RelA at several lysine residues 12, 13 , was active on the RelA mutant with replacement of lysine with arginine at position 310 (RelA(K310R); Supplementary Fig. 1c ). Massspectrometry analysis of SETD6 catalyzed methylation of RelA peptides spanning Lys310 (amino acids 300-320) demonstrated that SETD6 added only a single methyl moiety to RelA at Lys310 (Fig. 1c and Supplementary Fig. 2 ).
We raised antibodies to SETD6 (Supplementary Fig. 3 ) and the RelAK310me1 epitope (antiRelAK310me1). AntiRelAK310me1 specifically recognized RelAK310me1 peptides and did not detect unmodified RelA, RelA dimethylated or trimthrylated at Lys310, or numerous methylated histone peptides (Supplementary Fig. 4) . Furthermore, antiRelAK310me1 detected RelA(1-431) that had been methylated in vitro by SETD6 but failed to detect unmethylated RelA(1-431) or RelA(K310R) (Fig. 1d) . 
Figure 1 
A r t i c l e s
In cotransfection experiments, wildtype RelA was monomethyl ated by overexpressed SETD6, but RelA(K310R) was not (Fig. 1e) . Structurebased homology modeling indicated that SETD6 was most similar to the plant enzyme LSMT (Rubisco large subunit methyltrans ferase) 14 (Supplementary Fig. 5 ). On the basis of that homology, we identified SETD6 with replacement of tyrosine with alanine at posi tion 285 (SETD6(Y285A)) as a catalytic SETD6 mutant in vitro ( Fig. 1f and Supplementary Figs. 5 and 6 ) and found that overexpression of SETD6 led to more monomethylation of endogenous RelA at Lys310, but overexpression of SETD6(Y285A) did not (Fig. 1g) . Finally, deple tion of endogenous SETD6 protein in 293T cells by RNAmediated interference (RNAi) with two independent small interfering RNAs (siRNAs) resulted in less endogenous RelAK310me1 (Fig. 1h) . On the basis of these data, we conclude that SETD6 monomethylates RelA at Lys310 in vitro and is required for maintenance of physiological concentrations of RelAK310me1 in cells.
Chromatin association of RelAK310me1 under basal conditions
In unstimulated cells, most RelA is localized to the cytoplasm, but a population of RelA is present in the nucleus 15 . In this context, proteinprotein chromatinimmunoprecipitation (ChIP) assays in the absence of stimulation demonstrated association of RelA with histone H3 (Fig. 1i) . Moreover, we detected RelA by ChIP at the promoters of several target genes in unstimulated cells of many types (Supplementary Fig. 7 ). SETD6 was also present in the nucleus (Supplementary Fig. 3b ). RelA and SETD6 interacted in vitro and were coimmunoprecipitated from cells ( Supplementary Fig. 8a-d) . Thus, we reasoned that in contrast to most of RelA, which is localized to the cytoplasm in unstimulated cells 4 , the population of RelA that is monomethylated at Lys310 might reside and function in the nucleus. In support of our hypothesis, RelAK310me1 was biochemically frac tionated almost exclusively with chromatin in unstimulated 293T human embryonic kidney cells and U2OS human osteosarcoma cells (Fig. 1j,k) . Treatment with TNF, which activates NFκB 4 , resulted in much less RelAK310me1 at chromatin than did no stimulation (Fig. 1k) . On the basis of these data, we conclude that RelAK310me1 is present at chromatin in unstimulated cells.
Next we did ChIP assays with U2OS cells under basal conditions to determine if RelAK310me1 is bound to chromatin at the promoters of RelA target gene. RelAK310me1 occupied the promoters of several RelA target genes (IL8, IL1A, MYC and CCND1), and detection of this RelA species at target promoters was lost in U2OS cells treated with either of two independent siRNAs targeting SETD6 ( Fig. 2a and Supplementary  Fig. 9a ), as well as in U2OS cells stably expressing a short hairpin RNA A r t i c l e s (shRNA) targeting SETD6 ( Supplementary Fig. 10 ). Consistent with the results obtained with the cellular fractionation assays (Fig. 1j,k) , treatment with TNF resulted in less occupancy by RelAK310me1 at promoters of target genes both in U2OS cells and in the THP1 acute monocytic leukemia cell line ( Fig. 2b and Supplementary Fig. 9b ). Thus, monomethylation of RelAK310 is a chromatinassociated modi fication and is inversely correlated with activation of NFκB by TNF.
SETD6 attenuates transcription of RelA target genes
To investigate the relationship between SETD6 and the transcriptional activity of RelA, we cotransfected U2OS cells with an NFκBdriven reporter 16 and either SETD6 or SETD6(Y285A). The activity of this reporter was repressed by SETD6 in a dosedependent manner and required that the catalytic activity of SETD6 be intact (Fig. 2c) . In addi tion, depletion of SETD6 resulted in more reporter activity in unstimulated cells ( Supplementary Fig. 11 ) and after exposure to TNF (Fig. 2d) . These data suggested that SETD6 represses physiological transactivation by RelA.
To test that hypothesis, we depleted U2OS cells, THP1 cells and primary mouse bone marrow-derived macrophages (BMDMs) of SETD6 ( Fig. 2e) and measured mRNA for canonical NFκB targets in the presence or absence of NFκB stimulation 4 ( Fig. 2f-h ). In response to TNF, knockdown of SETD6 led to more expression of RelA target genes than their expres sion in control cells for all three cell types ( Fig. 2f-h ). We obtained similar results with mouse BMDMs stimulated with lipopolysaccharide (LPS; Fig. 2h , right). In addition, depletion of SETD6 resulted in higher basal expression of a subset of RelA target genes ( Supplementary Fig. 12 ). We noted that SETD6 did not methylate the RelA partner p50 ( Supplementary  Fig. 1d ) and, in contrast to known histone lysine methyltransferases such as G9a and GLP 9,17 , SETD6 did not methylate nucleosomes ( Supplementary  Fig. 1e ). Finally, genomewide geneexpression analysis of Rela −/− mouse embryonic fibroblasts (MEFs) 18 reconstituted with wildtype mouse RelA or mutant mouse RelA(K310R) showed that in the absence of stimulation, cells complemented with RelA(K310R) expressed more RelAregulated genes and expression of these genes was higher than that of cells comple mented with wildtype RelA (Supplementary Fig. 13 and Supplementary Data), which indicated involvement of Lys310 in regulating the expression of RelA target genes. Together these results indicate that SETD6mediated methylation of RelAK310 has an inhibitory effect on expression of many RelAregulated genes.
Attenuation of RelA-driven inflammatory responses by SETD6
Hyperactive NFκB has been linked to the development and progres sion of many types of cancer 8 . To investigate potential roles for SETD6
and the interaction of SETD6 and RelA in cellular transformation, we established U2OS cells with stable expression of shRNAs targeting SETD6 alone, RelA alone or SETD6 and RelA, or a control shRNA, and assessed cell transformation-associated properties (Fig. 3a,b and Supplementary Fig. 14) . Knockdown of SETD6 accelerated the proliferation rate of cells in a RelAdependent way relative to the pro liferation of control cells (Fig. 3a) . In addition, depletion of SETD6 conferred a 25fold greater ability of cells to form colonies in soft agar than that of control cells or cells depleted of RelA, and deple tion of both RelA and SETD6 reversed the anchorageindependent growth advantage provided by knockdown of SETD6 alone (Fig. 3b) . Depletion of SETD6 also led to higher cell proliferation rates in wild type 3T3 mouse embryonic fibroblasts but not in Rela −/− 3T3 cells (Fig. 3c) . Next, we depleted human U2OS cells and mouse 3T3 cells of endogenous SETD6 through the use of shRNA targeting the 3′ untrans lated region of human or mouse SETD6, respectively ( Fig. 3d,e) . We reconstituted the cells depleted of SETD6 with exogenous SETD6 or exogenous SETD6(Y285A) that lacked the 3′ untranslated region and was therefore resistant to shRNA. Complementation with wild type SETD6 reestablished a normal proliferative rate, whereas com plementation with SETD6(Y285A) failed to do so ( Fig. 3d,e) . These data suggest that the enzymatic activity of SETD6 regulates a RelA dependent effect on cell proliferation. In addition to being linked to cancer, NFκB-as a key regulator of inflammation-has also been linked to the etiology of inflammatory and autoimmune diseases 5, 8 . Analysis of published geneexpression data sets comparing peripheral blood mononuclear cells from patients suffering from rheumatoid arthritis, septic shock or juvenile idiopathic arthritis with control samples showed downregulation of SETD6 mRNA in the disease state ( Fig. 4a and Supplementary  Fig. 15 ). In addition, SETD6 expression was lower in patients with rheumatoid arthritis who responded to TNF inhibitors than in patients who were not responsive to this treatment ( Supplementary  Fig. 15b ), which suggested a role for NFκB in their rheumatoid arthritis disease.
The inverse correlation between SETD6 expression and NFκB linked inflammatory diseases and the observation that SETD6 attenu ates RelAdependent transactivation of cytokines such as interleukin 1α (IL1α) and TNF suggest that SETD6 might have a role in mitigat ing NFκBdriven inflammatory responses. Consistent with a negative role for SETD6 in NFκB signaling, in monocytic THP1 cells exposed to TNF, knockdown of SETD6 led to more production of the secreted cytokines TNF and IL6 than that of cells treated with control siRNA A r t i c l e s (Fig. 4b) . We next assessed the relationship between SETD6 depletion and cytokine production in mouse BMDMs. First, kinetic analysis showed that in response to TNF and LPS, the abundance of Il1a and Tnf mRNA was higher in cells depleted of SETD6 than in control cells across a range of time points ( Fig. 4c and Supplementary Fig. 16a ; SETD6knockdown efficiency; Fig. 16b ). Finally, depletion of SETD6 with two independent siRNAs in primary monocytederived dendritic cells isolated from human donors (Fig. 4e ) conferred a A r t i c l e s time and dosedependent increase in secretion of the cytokines TNF and IL6 in response to LPS stimulation (Fig. 4f) . Together these experiments indicate that SETD6 inhibits the production of a broad array of NFκBregulated cytokines in diverse cell types, includ ing antigenpresenting cells, which suggests that SETD6 is a critical repressor of RelAmediated inflammatory responses.
GLP ankyrin repeat is a RelAK310me1 effector domain
To understand the molecular basis of the repressive function associated with RelAK310me1, we screened CADOR microarrays 19 for protein motifs that could potentially act as transducers of this mark (Supplementary Fig. 17 ). Of the 268 proteins on the array, the RelAK310me1 peptide bound specifically to only one: the ankyrinrepeat domain of GLP (GLP(ANK); Fig. 5a ). Peptideprecipitation assays and measurement of dissociation constants independently confirmed and characterized the interaction between GLP(ANK) and RelAK310me1 ( Fig. 5b and Table 1 ). These data also demonstrated that except for the positivecontrol monomethylated and dimethylated H3K9 peptides 20 , other methylated histone peptides did not bind to GLP(ANK) (Fig. 5b) and that GLP(ANK) had similar binding affinities for RelAK310me1 and monomethylated H3K9 (ref. 20 ; Table 1 and Supplementary  Fig. 18 ). In addition, GLP(ANK) did not bind nonmethylated or tri methylated RelAK310 peptides ( Fig. 5b and Table 1 ), which indicated that the recognition of RelAK310 requires mono or dimethylation. Finally recombinant GLP(ANK) bound recombinant RelA(1-431) in coimmunoprecipitation experiments, but only after RelA(1-431) was methylated in vitro by SETD6 (Fig. 5c) . From these data we conclude that GLP(ANK) binds specifically to RelAK310me1 in vitro.
Next we investigated the ability of RelAK310me1 to be recognized by GLP in cells. Exogenous GLP coimmunoprecipitated overexpressed wildtype RelA but not RelA(K310R) (Fig. 5d and Supplementary  Fig. 8e ). In addition, SETD6 expression enhanced the interaction between endogenous GLP and RelA (Fig. 5e) . Decreasing the abundance of RelAK310me1 by depleting SETD6 via RNAi or TNF treatment inhibited the association of GLP with RelA (Fig. 5f,g ). These data suggest that in the absence of NFκB activation, RelA and GLP directly interact and that this interaction requires SETD6 dependent monomethylation of RelA at Lys310.
GLP and its heterodimeric partner G9a generate mono and dimethylated H3K9 at euchromatin to repress transcription 9, 21 , and methylation of H3K9 suppresses the expression of inducible inflam matory genes 10 . Our observations that methylation of RelA by SETD6 inhibited the expression of NFκB target genes and that GLP bound to RelAK310me1 suggested a model in which the content of histone H3 dimethylated at Lys9 (H3K9me2) is greater at RelAK310me1 occupied NFκB target genes in unstimulated cells because of the stabilization of GLP through its interaction with RelAK310me1. Two predictions of this model are as follows: first, under basal conditions and in a SETD6dependent manner, the chromatin of distinct RelA regulated gene promoters should be enriched for GLP and H3K9me2; and second, GLP should be required for SETD6 to inhibit expression of these RelAregulated genes. In support of the first prediction, ChIP assays demonstrated less occupancy by GLP and H3K9me2 at the promoters of IL8 and MYC in response to TNF stimulation ( Fig. 5h  and Supplementary Fig. 19 ), and knockdown of SETD6 with two independent siRNAs largely eliminated the baseline enrichment of GLP and H3K9me2 at these promoters ( Fig. 5h and Supplementary  Fig. 19 ). We obtained similar results with cells stably depleted of SETD6 by an shRNA approach (Supplementary Fig. 20) . In addi tion, induction of RelAK310me1 via SETD6 overexpression resulted in more occupancy by GLP and H3K9me2 at two RelA target promot ers (Supplementary Fig. 21a) . Thus, these data demonstrate a role for SETD6 and RelAK310me1 in stabilizing GLP activity at specific RelA target genes. 
A r t i c l e s
To investigate the functional interaction between GLP and SETD6 mediated attenuation of RelA transcriptional activity, we depleted cells of GLP and challenged them with TNF and found they had more IL8 and MYC mRNA than did cells treated with control shRNA (Supplementary Fig. 22a) . Moreover, the ability of SETD6 over expression to suppress baseline expression of IL8 and MYC mRNA was largely abrogated in cells depleted of GLP (Supplementary Fig. 22b ). These data indicate that inhibition of NFκB signaling by SETD6 occurs at chromatin and is mediated by a lysinemethylation network that connects SETD6 activity on RelA to GLP activity on H3K9.
RelA phosphorylation blocks GLP-RelAK310me1 interaction TNF stimulation initiates several activating phosphorylation events on RelA 7 , including phosphorylation at Ser311 by the atypical protein kinase PKCζ 11 . The molecular mechanism by which phosphorylation of Ser311 activates RelA is not known 11 . Because methylation of Lys310 and phosphorylation of Ser311 are coupled to opposing biological outcomes and the two modifications are in close physical proximity, we postulated that phosphorylation of Ser311 functionally inhibited the recognition of RelAK310me1 by GLP (Fig. 6a) . The ability of GLP(ANK) to bind RelAK310me1 peptides was abolished when Ser311 was phosphorylated, as determined by isothermal titration calorimetry ( Table 1 ) and peptideprecipitation assays (Fig. 6b) . Moreover, overexpression of constitutively active V5tagged PKCζ (PKCζ(ca)) 22 disrupted the endogenous inter action between RelA and GLP (Fig. 6c) . Consistent with the idea of a physiological role for RelA phosphorylated at S311 (RelAS311ph) in regulating the binding of GLP to RelA at chromatin, treatment with TNF (and overexpression of V5tagged PKCζ(ca)) resulted in a stronger RelAS311ph signal at chromatin, but a weaker RelAK310me1 signal (Fig. 6d) . Thus, we propose that phosphor ylation of Ser311 masks RelAK310me1 to prevent its recognition by GLP(ANK) (Fig. 6a) .
Antibody to the RelAS311ph epitope recognized the RelAS311ph mark regardless of methylation at Lys310 (Supplementary Fig. 23 ). In contrast, recognition of RelAK310me1 by antiRelAK310me1 was disrupted by phosphorylation of Ser311, as observed in dotblot assays with a dually modified peptide containing monomethylation of Lys310 and phosphorylation of Ser311 (Supplementary Fig. 23b ) or with a RelAK310me1 peptide phosphorylated at Ser311 in vitro by recombinant PKCζ (Fig. 6e) . These results also demonstrate that PKCζ phosphorylated Ser311 regardless of the monomethylation status of Lys310 (Fig. 6e) . Furthermore, detection of endogenous RelAK310me1 on RelA immunoprecipitated from cells overex pressing V5tagged PKCζ(ca) was much greater after in vitro dephosphorylation of the immunoprecipitated protein ( Fig. 6f and  Supplementary Fig. 23c ), which indicated that the RelAK310me1 epitope becomes exposed after removal of RelAS311ph and there fore demonstrated that the two marks probably cooccupy the same molecule. Together these findings suggest that TNFinduced phos phorylation of chromatinbound RelAK310me1 at Ser311 disrupts the association of GLP with RelA, thereby promoting activation of the population of NFκB target genes occupied by RelAK310me1.
A RelA methylation-phosphorylation switch in NF-kB signaling Consistent with the hypothesis outlined above, coexpression of V5 tagged PKCζ(ca) with SETD6 abrogated the greater occupancy of RelA target genes by RelAK310me1, GLP and H3K9me2 induced by SETD6 expression alone (Supplementary Fig. 21a ). In addition, SETD6 failed to inhibit the expression of IL8 and MYC when coexpressed with PKCζ(ca) (Supplementary Fig. 22b) . Indeed, expression of V5tagged PKCζ(ca) induced more expression of IL8 and MYC above baseline, whereas the ability of V5tagged PKCζ(ca) to antagonize SETD6 and stimulate the activation of RelA target genes was abro gated in cells depleted of GLP (Supplementary Fig. 22b) . Finally, the occupancy by RelAK310me1, GLP and H3K9me2 at promoters of four different RelA target genes involved in cell proliferation and inflam mation was lower after TNF stimulation in PKCζsufficient MEFs, but we did not observe these changes in PKCζdeficient (Prkcz −/− ) MEFs 23 ( Fig. 7a and Supplementary Fig. 24 ). In agreement with the ChIP results and as reported before 23 , TNF induction of the expres sion of Il1a and Il6 was largely attenuated in Prkcz −/− cells (Fig. 7b) . These results support a model in which the chromatin environment of NFκB target genes can be regulated by competing modifications of RelA by SETD6 and PKCζ, with the inert state linked to SETD6 mediated binding of GLP to RelAK310me1 and the active state linked to PKCζmediated disassociation of GLP from RelAK310me because of phosphorylation of Ser311 (Supplementary Fig. 25 ).
DISCUSSION
We have reported here the discovery of a previously unknown lysine methylation event that occurs on the transcription factor RelA, which is catalyzed by SETD6 and regulates the clinically important NFκB pathway. Monomethylation of nuclear RelA at Lys310 by SETD6 attenuated NFκB signaling by docking GLP (via its ankyrin repeats) at target genes to generate a silent chromatin state, effec tively rendering chromatinbound RelA inert. As deregulation of NFκB is linked to pathological inflammatory processes and cancer 8 and SETD6 inhibits NFκB signaling in diverse cell types, including primary human cells, SETD6 provides another link by which methyl ation of lysine residues of proteins and regulation of chromatin influ ence tumor suppression and antiinflammatory responses 2, 5 . SET7SET9 is a wellcharacterized PKMT with many protein sub strates 3 , including TNFdependent methylation of RelA at three dif ferent lysine residues 12, 13 . In contrast, SETD6 methylated RelA at a single residue (Lys310), and this occurred in the absence of stimula tion and was functionally suppressed by TNFinduced phosphoryla tion of RelA at Ser311. Thus, RelAK310me1 represents a specialized population of RelA that is not sequestered in the cytoplasm under basal conditions but is instead bound and quiescent at target pro moters. We postulate that methylation of transcription factors such as RelA can aid in the rapid and dynamic modulation of specific geneexpression programs by establishing transcriptional memory at marked genes 24 . In addition, the SETD6RelAGLPH3K9me2 network delineated here constitutes the first description to our knowledge of a lysinemethylation signaling cascade. We have also demonstrated that TNFinduced phosphorylation of RelA Ser311 terminated SETD6 action by blocking recognition of RelAK310me1 by GLP, which in turn led to chromatin relaxation and expression of RelA target genes. These findings provide the first example to our knowledge of a metazoan regulatory methylationphosphorylation switch on a nonhistone protein [25] [26] [27] . Together our results emphasize how the convergence and integration of multiple signals at chromatin can modify important biological and disease pathways.
METHODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/natureimmunology/. Accession codes. UCSDNature Signaling Gateway (http://www. signalinggateway.org): A001645, A002937 and A001934.
ONLINE METHODS
Plasmids and reagents. For overexpression in mammalian cells, the plasmids were as follows: pCAG FlagSETD6 wt, pCAG FlagSETD6(Y285A), pCAG FlagSmyd1, pCAG FlagSmyd2, pCAG FlagNSD2, pcDNARelA, pcDNA RelA(K310R) and pcDNA FlagGLP. The plasmid pcDNA3.1GSV5 PKCζ(ca) was a gift from J. Smith. For in vitro assays, RelA(1-431) and RelA(430-551) were subcloned into pGEX6P1. Single or double mutation of the sequence encoding RelA(1-431) was generated with the QuikChange sitedirected mutagenesis kit (Stratagene), and sequences were confirmed by DNA sequencing. The pGEXderived plasmids generated by mutagenesis were as follows: pGEX-RelA(K122R), pGEXRelA(K123R), pGEXRelA(K218R), pGEXRelA(K221R), pGEXRelA(K310R), pGEXRelA(K314R,K315R) and pGEXRelA(430-551). Sequence encoding p50 was subcloned into pGEX6P1 by standard methods. All enzymes in the PKMT library are in Supplementary  Table 1 ; enzymes used in Figure 1a and Supplementary Figure 1 are in Supplementary Table 2. NSD1(SET) was a gift from D. Reinberg.
For expression in insect cells, cDNA encoding fulllength SETD6 or various additional PKMTs was first cloned into pENTR3C and then recombined into Gateway pDEST20 with the Gateway LR Clonase II system (Invitrogen). Recombinant baculovirus were generated according to the manufacturer's protocol (Invitrogen). DH10Bac Escherichia coli cells were transfected with pDEST20 to generate recombinant baculovirus shuttle vector DNA. Sf9 Spodoptera frugiperda cells were then transfected with 2 µg baculovirus shuttle vector DNA with Cellfection II reagent (Invitrogen), and the baculovirus was amplified the times to obtain the optimal viral titer. For protein expression, baculovirus stocks were added to Sf9 cells grown in suspension at a density of 1 × 10 6 cells per ml, and transduced Sf9 cells were collected 2 d after trans duction. Sf9 cells were maintained in Sf900 II SFM media supplemented with 0.5% (vol/vol) penicillinstreptomycin.
Mouse RelA cDNA (Open Biosystems) was first cloned into the pENTR3C vector (Invitrogen) and then was recombined into the pBABEFLAGHA vector with the Gateway system as described above. RelA(K310R) was then generated with a QuikChange sitedirected mutagenesis kit (Stratagene).
Cell lines, transfection and transduction of retrovirus or lentivirus. Human 293T and U2OS cells, mouse 3T3 cells (wildtype and Rela −/− ; a gift from M. Covert and T.D. Gilmore) and MEFs (wildtype and Prkcz −/− ; a gift from J. Moscat) were grown in DMEM (Gibco) supplemented with 10% (vol/vol) FCS (Gibco) and 100 units/ml of penicillin and lglutamine. THP1 cells (American Type Culture Collection) were cultured in RPMI1640 medium (Gibco) supple mented with 10% (vol/vol) FCS (Gibco), 100 U/ml of penicillin and lglutamine, 0.05 mM βmercaptoethanol and 1× streptomycin. All cells were cultured at 37 °C in a humidified incubator with 5% CO 2 . Cells were transfected with the TransIT transfection reagent (for plasmids; Mirus) or DharmaFECT reagent (for siRNA; Dharmacon), according to the manufacturer's protocols. Human SETD6-specific siRNA sequences were 5′ACCTATGCCACAGACTTATT3′ (1) and 5′GACCACCACACTAAAGGTATT3′ (2) .
Mouse primary cells were isolated according to protocol 07064 of Rockefeller University and Institutional Animal Care and Use Committee protocol 9982 of Stanford University. Human biological samples were sourced ethically and their research use was in accordance with the terms of the informed consent received from each donor according to the Hertfordshire Ethics Committee Code 07/H0311/ 103. Mouse primary BMDMs were generated as described 28 . C57BL/6 bone marrow cells from femur and tibia were cultured for 7-8 d at 37 °C in 5% CO 2 in presence of 5 ng/ml of recombinant macrophage colony stimulating factor and IL3 (Peprotech). For knockdown experiments, siRNA directed against mouse SETD6 or control siRNA was transfected into cells with the HiPerFect transfection reagent according to the manufacturer's protocol (Qiagen), followed by stimulation experiments 48 h later. SETD6specific siRNA sequences for BMDMs were 5′GAACAAAGGATGAAACTGA3′ (1) and 5′GTGAGGAGGTGCTGACTGA3′ (2) . For human primary monocytederived dendritic cells, CD14 + cells were separated with MACS CD14 beads (positive selection) according to the manufacturer's protocols (Miltenyi). After separation, CD14 + cells were resuspended at a density of 1 × 10 6 cells per ml in RPMI1640 medium (plus lglutamine and 10% (vol/vol) heatinactivated FCS) containing human recombinant granulocytemonocyte colonystimulating factor (30 ng/ml) and human recombinant IL4 (20 ng/ml). Cells were differentiated for 5 d before transfection of siRNA by nucleofection according to the manufacturer's protocol (Amaxa) with the following minor alterations: siRNA was preplated into a 96well Ubottomed plates with a final concentration of 2 µM. Monocytederived dendritic cells were resuspended in Amaxa Nucleofecter buffer at a density of 1 × 10 6 cells per 20 µl, and 20 µl of the suspension was added to the plate containing siRNA. The plate was placed into the Amaxa device and the monocyte program EA100 was applied to all wells. After removal of the Amaxa plate, 100 µl prewarmed RPMI medium (plus 10% (vol/vol) heatinactivated FCS, penicillin and lglutamine) was added to each well, then cells were immediately removed from the Amaxa plate and added to a second flatbottomed plate containing an additional 100 µl of prewarmed media. SETD6specific siRNA sequences for mono cytederived dendritic cells were 5′TAATGCTGCCTCACGAACTGT3′ (1) and 5′TAGGAAATCCCAGCGCTCGTA3′ (2) . Mouse dendritic cells were isolated as described 29 . The FLB16 mouse melanoma cells used to make the conditioned media were a gift from E. Engleman.
Cells were transduced with retrovirus and lentivirus as described 30 . Lentivirus for control, SETD6specific and GLPspecific shRNA was from Santa Cruz Biotechnology. The human RelA shRNA target sequence is 5′GATTGAGGAGAAACGTAAA3′. For generation of the reconstituted cell lines, shRNA directed against the 3′ untranslated region of SETD6 was cloned into the shRNA vector pLentiLox3.7, and shRNA directed against wildtype SETD6 or SETD6(Y285A) was cloned into pWZL3FLAGhygro as an AscI PacI cassette. U2OS and 3T3 cells were first transduced with pLentiLox SETD6 shRNA plasmid, followed by selection with puromycin (2 µg/ml). Puromycin resistant cells were than transduced with pWZL3FlagSETD6 shRNA plasmid (wildtype SETD6 or SETD6(Y285A)) or with empty pWZLhygro, followed by selection for 4 d with hygromycin B (250 µg/ml; Invitrogen). The SETD6 shRNA target sequences were 5′CCTGTTCCCTGAAGGAACAGCAATA3′ (human) and 5′TGCTATTTGGCAGTTAGAATCAAAG3′ (mouse). Where indicated, cells were stimulated with mouse TNF (10-20 ng/ml; R&D Systems) or LPS (10-100 ng/ml; Sigma).
Enzyme-linked immunosorbent and Luminex bead-based cytokine assays.
Enzymelinked immunosorbent assays were done as described 31 Gene-expression profiling. Gene expression arrays were done at the Stanford Functional Genomics Facility with a MouseRef8 wholegenome array, according to the manufacturer's protocol (Illumina), and included two independent biological replicates (genes analyzed, Supplementary Fig. 13 ). Genes were selected when the mean change (fold) was over 1.5. P values for Venn and pie diagrams were calculated with Fisher's exact test and the χ 2 test, respectively. SETD6 mRNA in rheumatoid arthritis, septic shock and juvenile idiopathic arthritis. A review of available literature involving microarray studies for rheumatoid arthritis, septic shock and juvenile idiopathic arthritis was used to identify four studies that met the criteria described below [32] [33] [34] [35] [36] [37] . For rheumatoid arthritis, data were retrieved from the Stanford Microarray Database with the filtering criteria implemented before 32 and from the Gene Expression Omnibus database (accession code, GDS3628) 33 . Data were retrieved from the Gene Expression Omnibus database for septic shock (accession code, GSE8121) 35, 37 and juvenile idiopathic arthritis (accession codes, GSE13501 and GSE13849) 34 . Only studies with microarray platforms that contained SETD6 probes were considered 36 . In the study selected for its data on rheumatoid arthritis 32 , which used custom cDNA microarrays deposited in Stanford Microarray Database, initial analysis showed that two of the three SETD6 probes on the array (IMAGE 213233 and IMAGE 66711) were of poor quality because of a low signal/background ratio in both channels (mean ratio, 3.7 and 5.1, respectively; this resulted in the removal of many data points by the filtering threshold of 2.5 used 32 ), and these results were therefore removed from the analysis.
The remaining probe (IMAGE 1699773) had a much higher mean ratio (13.5), well above the threshold, and was thus used in the analysis. Final normalized data were retrieved from either of the databases noted above with filtering criteria described in the respective publications 36 . The results of any data sets containing multiple highquality probes representing SETD6 were averaged before statistical analysis. For analysis of significance, a twotailed independent ttest with unequal variance was applied to each study containing a comparison between a disease group and a healthy control group or, in one case, patients with rheumatoid arthritis that responded to infliximab versus patients whose rheumatoid arthritis did not respond to infliximab.
In vitro lysine-methylation assay. These assays were done as described 38 . Recombinant RelA derivatives and peptides, recombinant nucleosomes (a gift from R. Kingston and M. Simon) or purified nucleosomes of HeLa cervical cancer cells 39 were incubated overnight at 30 °C with recombinant PMKTs and 0.1 mM Sadenosylmethionine (AdoMet; Sigma) or 2 mCi 3 Hlabeled Sadenosylmethionine (AdoMet; Amersham) in methylation buffer contain ing 50 mM TrisHCl, pH 8.0, 10% (vol/vol) glycerol, 20 mM KCl, 5 mM MgCl2 and 1 mM phenylmethyl sulfonyl fluoride. Reaction mixtures were resolved by SDSPAGE, followed by autoradiography, immunoblot analysis or Coomassie staining (Pierce). Reactions with peptides were analyzed by dot blot or mass spectrometry.
Mass spectrometry. Before mass spectrometry, peptides were diluted in 0.1% (vol/vol) acetic acid for desalting with C18 stage tips ('stop and go' extrac tion tips) made inhouse as described 40 . Samples were then loaded with an Eksigent AS2 autosampler into fused silica capillary columns (inner diameter, 75 µm) packed with 15 cm of C18 reversedphase resin (5 µm in diameter with a pore size of 200 Å; Magic C18; Michrom BioResources). Capillary columns were constructed with an electrospray tip for nanoflow reversed phase highperformance liquid chromatography-tandem mass spectrometry on a hybrid linear quadrupole iontrap Orbitrap mass spectrometer (Thermo Electron). Peptides were resolved with a gradient of 5-35% buffer B in 110 min gradient (buffer A, 0.1 M acetic acid; buffer B, 70% (vol/vol) acetonitrile in 0.1 M acetic acid) with a flow rate of approximately 200 nl/min on an Agilent 1200 binary HPLC system.
The Orbitrap was operated with a resolution of 30,000 for a full mass spectrometry spectrum, followed by seven subsequent datadependent tandem mass spectrometry spectra collected in the ion trap after electron transfer dissociation of peptides. Peptides selected for tandem mass spectro metry were put on an exclusion list for 60 s to avoid duplicate spectra. All spectra were analyzed with Qual Browser (version 2.0.7, Thermo Scientific), and the identity of each peptides was confirmed by manual inspection of tandem mass spectrometry spectra.
Interaction studies, immunoblot analysis, calf intestinal alkaline phosphatase assays, kinase assays and antibodies. Cell extracts were prepared by lysis of PBSwashed cells in radioimmunoprecipitation assay lysis buffer (50 mM TrisHCl, pH 8, 150 mM NaCl, 1% (vol/vol) Nonidet P40, 0.5% (vol/vol) deoxycholate, 0.1% (vol/vol) SDS, 1 mM dithiothreitol and protease inhibitor 'cocktail' (diluted 1:100; P8340; Sigma). Protein concentrations were measured with the Bradford reagent (BioRad). Equal amounts of protein for each sample were mixed with Laemmli sample buffer (4% (vol/vol) SDS, 20% (vol/vol) glycerol, 10% (vol/vol) 2mercaptoethanol and 0.125 M Tris·HCl, pH 6.8), then were heated for 5 min at 95 °C and separated by SDSPAGE.
For analysis of the presence of monomethylated Lys310 and phosphorylated Ser311 on the same molecule, immunoprecipitated endogenous RelA from 293T cells transfected with PKCζ(ca) was washed three times with radio immunoprecipitation assay buffer. Immunoprecipitated RelA bound on protein A-protein G beads was separated into two equal aliquots that were mock treated or were treated for 1 h at 37 °C with calf intestinal alkaline phosphatase (New England Biolabs) before immunoblot analysis. Recombinant PKCζ for the kinase assays was from Invitrogen (P2268). Biochemical fractionation, glutathione Stransferase precipitation assays, immunofluorescence staining, and proteinprotein ChIP experiments were done as described 38, 41, 42 .
Antibodies used were as follows: antiGLP (sc81260; Santa Cruz Biotechnology), antip65 (sc8008 AC; Santa Cruz Biotechnology), antiFlag
